SynthesisWorld journal of urology2017
Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.
Synthesis in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Diagnostic performance of radiomics for detecting and characterising upper tract urothelial carcinoma (UTUC): a systematic review.World journal of urology · 2026Pooled it
- Prognostic nutritional index before surgical treatment may serve as a prognostic biomarker for patients with upper tract urothelial carcinoma: A systematic review and meta-analysis.Frontiers in nutrition · 2022Pooled it
- Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.The Cochrane database of systematic reviews · 2019Pooled it
- Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.World journal of urology · 2018Pooled it
- Trial
- Overweight status predicts improved overall survival after radical nephroureterectomy for upper tract urothelial carcinoma.The Canadian journal of urology · 2026Article
- Reassessing age limits: Outcomes of radical nephroureterectomy in octogenarian patients with upper tract urothelial carcinoma.Investigative and clinical urology · 2026Article
- Deep learning for prognostic stratification and biomarker exploration in upper tract urothelial carcinoma: a multicenter retrospective cohort study.International journal of surgery (London, England) · 2026Article
- Radiomics-based interpretable machine learning model from multiphasic CT imaging for predicting pathological grade in upper tract urothelial carcinoma: a multicenter study.Frontiers in oncology · 2026Article
- Impact of dialysis on intravesical recurrence and survival outcomes in upper tract urothelial cancer patients undergoing radical nephroureterectomy.Renal failure · 2025Article
- Development and validation of a predictive model for postoperative metastasis of upper tract urothelial carcinoma after radical nephroureterectomy and analysis of risk factors for different metastatic sites: a multicenter study.International urology and nephrology · 2025Article
- Machine Learning-Based Gene Expression Analysis to Identify Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.Cancers · 2025Article
- Article
- Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy for localized upper urinary tract urothelial carcinoma: A multicenter study.Investigative and clinical urology · 2025Article
- Using apparent diffusion coefficient maps and radiomics to predict pathological grade in upper urinary tract urothelial carcinoma.BMC medical imaging · 2024Article
- Article
- No difference in oncological outcomes and perioperative complications between patients with ESRD with unilateral and bilateral UTUC receiving radical nephroureterectomy.Scientific reports · 2024Article
- Adoption of robot-assisted radical nephroureterectomy permits a minimally invasive option for management of upper tract urothelial carcinoma in geriatric patients: comparison with non-geriatric patients with intermediate-term oncologic follow-up.Journal of robotic surgery · 2024Article
- The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features.International urology and nephrology · 2024Article
- Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy in nonmetastatic upper tract urothelial carcinoma with ≤pT2.Central European journal of urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper tract urothelial carcinoma (UTUC) is a rare and heterogeneous disease. Several clinical and biological prognostic factors have been identified in multi-institutional collaborative works with the aim of helping decision-making in pursuit of tailored individual patient care. This review provides an overview of these existing prognostic factors and predictive tools for the management of patients with UTUC.
methodsA systematic literature search was performed using PubMed/MEDLINE, Web of Science and Scopus databases regarding articles published in English between January 2000 and November 2015 according to PRISMA guidelines. Thresholds of 100 and 300 patients were applied for studies on biomarkers and clinical studies, respectively. All the studies on predictive tools were included for analysis. Outcomes of interest were features associated with advanced-stage UTUC, disease recurrence and survival.
resultsA total of 116 studies were included in this review. These large and/or multi-institutional studies have confirmed the prognostic value of standard pathological factors (i.e., tumor stage, grade and lymph node metastasis) and identified novel features such as lymphovascular invasion, tumor architecture, multifocality, concomitant CIS, variant histology and biomarker status among others. Based on these variables, several predictive tools have been developed; however, they often lack of validation. The value of these features and tools needs prospective testing.
conclusionEfforts provided by international collaboration groups have permitted to validate established features and identify new features of biologically and clinically aggressive UTUC. Further investigation on prognostic factors and biomarkers is still needed to assess the benefit of these features and tools on clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.